Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Prostate Cancer Patients Clinical Trial

Official title:
A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Repaglinide (CYP2C8 Substrates) and Bupropion (CYP2B6 Substrates) in Prostate Cancer Patients

Status Recruiting

Clinical Trial Summary

The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04664725
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Yuya Wang, Ph.D
Phone	13918749176
Email	wangyuya@hrglobe.cn
Status	Recruiting
Phase	Phase 1
Start date	June 1, 2020
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03795207` - Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)	Phase 2
Completed	`NCT02715583` - C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer	Early Phase 1
Completed	`NCT04676035` - The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole	Phase 1
Recruiting	`NCT03258320` - A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis	Phase 1